secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACADIA PHARMACEUTICALS INC (ACAD)
CIK:        0001070494
Form:       8-K
Filed at:   2022-11-02T23:59:59+00:00
Accession:  0000950170-22-021222
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acadia Q3 net sales $130.7M (-1% YoY), net loss widens; trofinetide PDUFA Mar 2023
--------------------------------------------------------------------------------

- Q3 net sales $130.7M (-1% YoY); net loss $27.2M ($0.17 loss/share) vs $14.5M loss a year ago.
- FY 2022 NUPLAZID guidance narrowed to $510-520M from $510-540M; R&D and SG&A guides trimmed.
- FDA accepted trofinetide NDA for Rett syndrome with priority review; PDUFA action date March 12, 2023.
- President Serge Stankovic to retire at year-end; search ongoing. Adora Ndu appointed to Board of Directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070494/000095017022021222/0000950170-22-021222-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070494/000095017022021222/acad-20221102.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-021222

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer